Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS-COV-2

Osivax's novel oligoDOM® technology, designed to induce potent T-cell responses, will serve as the basis for this broad-spectrum vaccine against COVID-19

Osivax, a French biotechnology company pioneering a new class of universal vaccines against ever-mutating viruses thanks to its patented oligoDOM® technology, and CDMO 3P Biopharmaceuticals are collaborating on the development of a broad-spectrum vaccine against COVID-19. 3P’s role will focus on process scale-up and cGMP production of Osivax’s vaccine for use in Phase I clinical trials.

Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS-COV-2

The benefit of this vaccine compared to others lies mainly in the fact that it targets a part of the virus that is much less prone to mutation: the nucleocapsid. Osivax oligoDOM® (OVX313) technology enables the transformation of the nucleocapsid into a highly immunogenic antigen to trigger potent B- and T-cell immune responses.

Current research efforts are mostly directed towards Spike, an antigen on the surface of the coronavirus, which have shown to vary from variant to variant. By targeting the nucleocapsid, an internal antigen that is much less prone to mutation, Osivax’s vaccine would provide a universal approach to combat all current and future SARS-COV-2 variants.

Dámaso Molero, CEO of 3P Biopharmaceuticals said: “To be able to say that we are collaborating with Osivax on such a novel and important technology platform such as oligoDOM® to help prevent pandemics like COVID-19, is a real achievement for 3P“.

This collaboration is also a step forward for Osivax in fulfilling its mission to pioneer a new class of universal vaccine: Alexandre Le Vert, CEO of Osivax, stated, “The development of our pan-coronavirus vaccine will provide additional evidence on the relevance of our universal vaccination approach and the potential of oligoDOM® vaccines to revolutionize the prevention of ever-evolving global infectious diseases.

View the full press release here

Our dedicated team of specialists will be happy to discuss any of your CDMO supply chain needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

BrainEver and 3P Biopharmaceuticals collaborate on development of recombinant human homeoprotein Engrailed-1

Published: 15th November 2022
3P Bio will focus on the transfer of the production process as well as the cGMP manufacturing of the drug substance to be used in Phase I and II clinical trials. The novel drug could cure neurodegenerative diseases such as Amyotrophic Lateral Sclerosis.
Read more

3P Biopharmaceuticals awards the prize for the best Master’s Thesis (TFM)

Published: 3rd October 2022
At the closing of the fifth edition of the Master in Galenic Design and Manufacturing in the Pharmaceutical Industry of the University of Navarra.
Read more

3P Biopharmaceuticals among the 100 best companies to work for in Spain

Published: 27th September 2022
The prestigious ranking is based on an exhaustive questionnaire that Actualidad Económica prepares and publishes every year, and which seeks to evaluate and reward those companies whose human resources management makes them benchmarks.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.